Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Jacob K McPhersonDepartment of Pharmacy Practice and Translational Research, University of Houston, Houston, Texas, USA.
Julian G HurdleCenter for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Department of Translational Medical Sciences, Texas A&M Health Science Center, Houston, Texas, USA.ORCID 0000-0003-2214-8105
Matthew L BakerDepartment of Biochemistry and Molecular Biology, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.
Tahir HussainDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas, USA.
Ashok KumarDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas, USA.ORCID 0000-0001-8571-2848
Kevin W GareyDepartment of Pharmacy Practice and Translational Research, University of Houston, Houston, Texas, USA.ORCID 0000-0003-2063-7503
Funding
Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionR01AI139261 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Kevin W Garey, Julian G Hurdle · 2018 to 2026
$6.0M
TWEAK/Fn14/UPR Signaling in Skeletal Muscle WastingR01AR081487 · NIAMS · UNIVERSITY OF HOUSTON · PI ASHOK KUMAR · 2023 to 2026
$2.1M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
Antimicrobial Resistance Training Program in the Texas Medical Center (AMR-TPT)T32AI179595 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Cesar Augusto Arias · 2024 to 2026
$1.0M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 2R01AI139261HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) T32 A1141349NIAID NIH HHS R01 AI139261NIAID NIH HHS T32 AI141349NIAID NIH HHS T32 AI179595NIAMS NIH HHS R01 AR081487
6 · The paper itself
Abstract
Ibezapolstat (IBZ), a first-in-class antibiotic targeting the PolC-type DNA polymerase III alpha-subunit (PolC) in low G + C bacteria, is in clinical development for the treatment of
Indexed as
Anti-Bacterial AgentsClostridioides difficileClostridium InfectionsDNA Polymerase IIIMicrobiotaBacterial ProteinsHumansMicrobial Sensitivity TestsPhylogenyPurine NucleosidesAnti-Bacterial AgentsBacterial ProteinsDNA Polymerase IIIIbezapolstatPurine NucleosidesBacillotaClostridioides difficileDNA replicationibezapolstatLachnospiraceaeOscillospiraceaePolC-type DNA polymerase III
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The microbiome-restorative potential of ibezapolstat for the treatment of · full record | OpenQuestion